SCHEMBL15516474

SCHEMBL15516474

O=C1CCCN1Cc1cccc(I)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
CDC7 O00311 1/20 0.47
PLK4 O00444 1/20 0.47
AURKA O14965 1/20 0.47
MAPK13 O15264 1/20 0.47
PDPK1 O15530 1/20 0.47
DYRK3 O43781 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
ERBB2 P04626 1/20 0.47
NTRK1 P04629 1/20 0.47
PRKCG P05129 1/20 0.47
FYN P06241 1/20 0.47
CSF1R P07333 1/20 0.47
RET P07949 1/20 0.47
IGF1R P08069 1/20 0.47
ROS1 P08922 1/20 0.47
PARP1 P09874 1/20 0.47
KIT P10721 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30799059 0.95 L3MBTL1 (0.65) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL31512198 0.94 L3MBTL1 (0.68) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL27165584 0.94 L3MBTL1 (0.68) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL7935783 0.85 SIGMAR1 (0.46) L3MBTL1HTR2CSIGMAR1
SCHEMBL14047566 0.82 HTR2C (0.41) L3MBTL1HTR2CFAAHKMT2ASIGMAR1
SCHEMBL24732719 0.81 L3MBTL1 (0.58) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL13181473 0.81 L3MBTL1 (0.58) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL15152924 0.81 L3MBTL1 (0.58) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL11010729 0.81 L3MBTL1 (0.58) L3MBTL1CDC7PLK4AURKAMAPK13
SCHEMBL2720932 0.81 L3MBTL1 (0.58) L3MBTL1CDC7PLK4AURKAMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249125-B2 Pyrazole derivatives as p38 MAP inhibitors RESPIVERT LIMITED (GB) 2016-02-02 US disclosed
US-9249125-B2 Pyrazole derivatives as p38 MAP inhibitors RESPIVERT LIMITED (GB) 2016-02-02 US disclosed
US-9249125-B2 Pyrazole derivatives as p38 MAP inhibitors RESPIVERT LIMITED (GB) 2016-02-02 US disclosed
US-20150203475-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS TOPIVERT PHARMA LIMITED (GB) 2015-07-23 US disclosed
US-20150203475-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS TOPIVERT PHARMA LIMITED (GB) 2015-07-23 US disclosed
US-20150203475-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS TOPIVERT PHARMA LIMITED (GB) 2015-07-23 US disclosed
EP-2890693-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS Respivert Limited (GB) 2015-07-08 EP disclosed
WO-2014033448-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS RESPIVERT LIMTED (GB) 2014-03-06 WO disclosed
WO-2014033448-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS RESPIVERT LIMTED (GB) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203475-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS SYK, FYN, MAPK1 L3MBTL1 4380/4885CDC7 1923/4885PLK4 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.